Spots Global Cancer Trial Database for recurrent ovarian epithelial cancer
Every month we try and update this database with for recurrent ovarian epithelial cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | NCT00005046 | Ovarian Cancer Primary Periton... | chemotherapy paclitaxel | 21 Years - | GOG Foundation | |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | NCT00569673 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim pegfilgrastim docetaxel trabectedin | 18 Years - 120 Years | GOG Foundation | |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | NCT00006036 | Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | cisplatin lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02122185 | Brenner Tumor Malignant Ascit... Malignant Pleur... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Ovaria... Stage IV Primar... | metformin hydro... placebo Chemotherapy | 18 Years - | University of Chicago | |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | NCT00390234 | Fallopian Tube ... Female Reproduc... Ovarian Carcino... Ovarian Sarcoma Recurrent Ovari... Recurrent Uteri... Stage III Ovari... Stage III Uteri... Stage IV Ovaria... Stage IV Uterin... Uterine Carcino... Uterine Leiomyo... | ziv-aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer | NCT00337233 | Breast Cancer Fatigue Ovarian Cancer Psychosocial Ef... | yoga therapy | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | NCT01846520 | Healthy Subject Localized Trans... Metastatic Tran... Psychosocial Ef... Recurrent Bladd... Recurrent Cervi... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Recurrent Trans... Recurrent Ureth... Recurrent Uteri... Regional Transi... Stage II Bladde... Stage II Renal ... Stage II Urethr... Stage IIA Cervi... Stage IIA Colon... Stage IIA Gastr... Stage IIA Ovari... Stage IIA Ovari... Stage IIA Pancr... Stage IIA Recta... Stage IIA Uteri... Stage IIB Cervi... Stage IIB Colon... Stage IIB Gastr... Stage IIB Ovari... Stage IIB Ovari... Stage IIB Pancr... Stage IIB Recta... Stage IIB Uteri... Stage IIC Colon... Stage IIC Ovari... Stage IIC Ovari... Stage IIC Recta... Stage III Bladd... Stage III Pancr... Stage III Renal... Stage III Ureth... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Gast... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Gast... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Uter... Stage IV Bladde... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Urethr... Stage IVA Cervi... Stage IVA Colon... Stage IVA Recta... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Colon... Stage IVB Recta... Stage IVB Uteri... Ureter Cancer Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIB Lung... | educational int... telephone-based... quality-of-life... questionnaire a... | 18 Years - | City of Hope Medical Center | |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | NCT00278343 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | cediranib malea... laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer | NCT00004177 | Ovarian Cancer | filgrastim peripheral bloo... indium In 111 m... yttrium Y 90 mo... | 18 Years - 80 Years | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | NCT00003135 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer | fluorouracil pegylated lipos... hyperthermia tr... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer | NCT00006356 | Ovarian Cancer | carboplatin cisplatin conventional su... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | NCT00066651 | Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton... | SS1(dsFv)-PE38 ... | 18 Years - | National Cancer Institute (NCI) | |
| Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | NCT00010179 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02050009 | Ovarian Papilla... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | metformin hydro... carboplatin paclitaxel laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01962948 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | paclitaxel ganetespib laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | NCT00003670 | Ovarian Cancer Primary Periton... | arzoxifene hydr... | 18 Years - | Eli Lilly and Company | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | NCT00093496 | Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00825201 | Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | paclitaxel albu... liquid chromato... mass spectromet... pharmacological... laboratory biom... | 19 Years - | City of Hope Medical Center | |
| Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00041041 | Primary Periton... Recurrent Ovari... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | NCT00287885 | Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... Sarcoma Vaginal Cancer Vulvar Cancer | docetaxel | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005029 | Ovarian Cancer Primary Periton... | topotecan hydro... | - 120 Years | GOG Foundation | |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | NCT00012090 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bicalutamide goserelin aceta... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | NCT00002819 | Ovarian Cancer | carboplatin cyclophosphamid... mitoxantrone hy... paclitaxel autologous bone... peripheral bloo... | - 65 Years | GOG Foundation | |
| Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers | NCT00684801 | Colorectal Canc... Lung Cancer Ovarian Cancer Pancreatic Canc... | questionnaire a... quality-of-life... | 18 Years - | Case Comprehensive Cancer Center | |
| Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00041080 | Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | tamoxifen citra... thalidomide laboratory biom... | - | National Cancer Institute (NCI) | |
| Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | NCT00004895 | Colorectal Canc... Constipation, I... Extrahepatic Bi... Gastric Cancer Gastrointestina... Nausea and Vomi... Ovarian Cancer Pancreatic Canc... Peritoneal Cavi... Small Intestine... | octreotide acet... | 18 Years - | Northwestern University | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer | NCT00003080 | Ovarian Cancer | endocrine-modul... melphalan mitoxantrone hy... tamoxifen citra... thiotepa peripheral bloo... | 18 Years - 60 Years | Fred Hutchinson Cancer Center | |
| CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00096239 | Fallopian Tube ... Ovarian Cancer Primary Periton... | CP-547,632 | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer | NCT00072410 | Ovarian Cancer | 90Y-hu3S193 111In-hu3S193 | 18 Years - | Ludwig Institute for Cancer Research | |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT01100372 | Fallopian Tube ... Ovarian Cancer Primary Periton... | gemcitabine hyd... liposome-encaps... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer | NCT00003439 | Cancer | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00023907 | Ovarian Cancer Primary Periton... | paclitaxel | - | GOG Foundation | |
| Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00003548 | Cancer | aminocamptothec... | 18 Years - | NYU Langone Health | |
| Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer | NCT00002487 | Ovarian Cancer | dipyridamole methotrexate | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | NCT01126346 | Advanced Malign... Carcinoma of th... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Colon... Recurrent Malig... Recurrent Ovari... Recurrent Ovari... Stage III Colon... Stage III Ovari... Stage III Ovari... Stage IV Colon ... Stage IV Ovaria... Stage IV Ovaria... Unspecified Chi... | HIPEC Orientati... Consultation wi... Questionnaires | - | Wake Forest University Health Sciences | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005029 | Ovarian Cancer Primary Periton... | topotecan hydro... | - 120 Years | GOG Foundation | |
| Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer | NCT00002671 | Ovarian Cancer | aminocamptothec... | 18 Years - | NYU Langone Health | |
| Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00022659 | Primary Periton... Recurrent Ovari... Stage IV Ovaria... | bevacizumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | NCT00245050 | Breast Cancer Drug/Agent Toxi... Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pyridoxine hydr... Placebo doxorubicin HCL... | - | Case Comprehensive Cancer Center | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer | NCT00096395 | Recurrent Ovari... Recurrent Prima... | gemcitabine hyd... sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Quality-of-Life Assessment in Patients With Ovarian Cancer | NCT00003772 | Ovarian Cancer | quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer | NCT00002928 | Ovarian Cancer | paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Quality-of-Life Assessment in Patients With Ovarian Cancer | NCT00003772 | Ovarian Cancer | quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00016289 | Primary Periton... Recurrent Ovari... | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | NCT01126346 | Advanced Malign... Carcinoma of th... Ovarian Sarcoma Ovarian Stromal... Pseudomyxoma Pe... Recurrent Colon... Recurrent Malig... Recurrent Ovari... Recurrent Ovari... Stage III Colon... Stage III Ovari... Stage III Ovari... Stage IV Colon ... Stage IV Ovaria... Stage IV Ovaria... Unspecified Chi... | HIPEC Orientati... Consultation wi... Questionnaires | - | Wake Forest University Health Sciences | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00114166 | Fallopian Tube ... Ovarian Cancer Primary Periton... | topotecan hydro... | 18 Years - 120 Years | GOG Foundation | |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | NCT00005046 | Ovarian Cancer Primary Periton... | chemotherapy paclitaxel | 21 Years - | GOG Foundation | |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | NCT00063895 | Recurrent Non-s... Recurrent Ovari... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Non-sm... Stage IV Ovaria... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... | erlotinib hydro... pharmacological... pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00872989 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel vandetanib | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | NCT00617188 | Ovarian Cancer | Fulvestrant | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00019461 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboxyamidotri... chemotherapy | 18 Years - | National Cancer Institute (NCI) | |
| S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer | NCT00043082 | Ovarian Cancer Peritoneal Cavi... | carboplatin pegylated lipos... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00089362 | Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas... | alvespimycin hy... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer | NCT00005807 | Breast Cancer Ovarian Cancer Unspecified Adu... | BMS-247550 | 18 Years - 120 Years | Albert Einstein College of Medicine | |
| Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer | NCT00002671 | Ovarian Cancer | aminocamptothec... | 18 Years - | NYU Langone Health | |
| Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00028912 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bortezomib carboplatin | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer | NCT00003297 | Ovarian Cancer | mitoxantrone hy... thiotepa topotecan hydro... peripheral bloo... | 18 Years - | Georgetown University | |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00436501 | Fallopian Tube ... Malignant Tumor... Recurrent Ovari... | docetaxel ziv-aflibercept laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer | NCT00002894 | Ovarian Cancer Primary Periton... | carboplatin cisplatin paclitaxel | - | National Cancer Institute (NCI) | |
| S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | NCT00003120 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors | NCT00433407 | Breast Cancer Lung Cancer Ovarian Cancer Prostate Cancer Sarcoma Unspecified Adu... | trastuzumab | - | Jonsson Comprehensive Cancer Center | |
| Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer | NCT01927393 | Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Stage III Pancr... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIC Ovar... Stage IIIC Ovar... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... | palliative care educational int... quality-of-life... questionnaire a... telephone-based... | 21 Years - | City of Hope Medical Center | |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00436501 | Fallopian Tube ... Malignant Tumor... Recurrent Ovari... | docetaxel ziv-aflibercept laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | NCT01200797 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | SJG-136 laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | NCT00081276 | Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | triapine cisplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | NCT00610740 | Cervical Cancer Endometrial Can... Ovarian Cancer | topical gemcita... therapeutic con... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | NCT00113373 | Primary Periton... Recurrent Ovari... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
